SM-130686

From WikiMD's WELLNESSPEDIA

SM-130686 is a chemical compound that is classified as a non-peptide vasopressin V1b receptor antagonist. It was developed by Shionogi, a Japanese pharmaceutical company, and has been studied for its potential therapeutic applications in various neurological disorders and endocrine disorders.

Chemistry[edit]

SM-130686 is a non-peptide compound, which means it does not contain amino acid sequences typically found in peptides. This characteristic gives it certain advantages over peptide-based drugs, such as improved stability and potential for oral administration.

Mechanism of Action[edit]

SM-130686 works by blocking the vasopressin V1b receptor. Vasopressin, also known as antidiuretic hormone (ADH), is a neurotransmitter that plays a key role in maintaining water balance in the body. The V1b receptor is one of three types of vasopressin receptors and is primarily found in the pituitary gland and certain areas of the brain. By blocking this receptor, SM-130686 can potentially modulate the effects of vasopressin.

Potential Therapeutic Applications[edit]

Research has suggested that SM-130686 may have potential therapeutic applications in the treatment of various neurological and endocrine disorders. These include depression, anxiety disorders, post-traumatic stress disorder (PTSD), and Cushing's syndrome.

In preclinical studies, SM-130686 has shown promise in reducing depressive-like behaviors in animal models. It has also been suggested that the compound could be useful in treating anxiety disorders and PTSD, as these conditions have been linked to abnormalities in the vasopressin system.

In the context of endocrine disorders, SM-130686 has been studied for its potential use in treating Cushing's syndrome. This condition is characterized by an overproduction of cortisol, a hormone that is regulated by the vasopressin V1b receptor. By blocking this receptor, SM-130686 could potentially help to normalize cortisol levels.

Development Status[edit]

As of now, SM-130686 is still in the experimental stage and has not been approved for clinical use. Further research is needed to fully understand its safety, efficacy, and potential therapeutic applications.

See Also[edit]


This Chemical compound-related article is a stub. You can help WikiMD by expanding the page.

This article is a stub related to pharmacology. You can help WikiMD by expanding it!


  • SM-130686
    SM-130686

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=SM-130686&oldid=6333095"